• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

‘Remarkable interest’: Madrigal touts early launch progress for first MASH drug Rezdiffra...

cafead

Administrator
Staff member
  • cafead   May 07, 2024 at 06:42: PM
via With $1.1 billion cash on Madrigal Pharmaceuticals’ balance sheet, CEO Bill Sibold believes the company can “fully resource” the launch of Rezdiffra, the first FDA-approved therapy for fatty liver disease.

article source
 

<